These compounds can improve drug sensitivity in resistant cancer cells by reducing drug efflux and increasing intracellular chemotherapeutic accumulation by down-regulating MDR1 and interfering with the ATP-binding domain of P-glycoprotein [261]. The gene discussed is ABCB1; the disease is cancer.